

April 2023 PDL/DUR Board Meeting Minutes

Date: April 26, 2023

Members Present: Barnhill, Blake, Blank, Brown, Caldwell, Jost, McGrane

Members Absent: Anglim, Nauts, Putch, Stone, Turnsplenty

Others Present: Shannon Sexauer, Dani Feist, Katie Hawkins (DPHHS); Kathy Novak (Magellan); Bahny, Miranda, Woodmansey (Mountain Pacific); and representatives from the pharmaceutical industry.

Public Comment: Speaker information is as follows:

- Natalie Rose, Gilead – Epclusa®
- Mariola Vazquez, Dermavant – Vtama®
- Erin Nowak, AbbVie – Rinvoq®, Skyrizi®
- Uche Mordi, Bristol Myers Squibb – Sotyktu®

Meeting Minute Review: The meeting minutes from the DUR Board meeting on February 15, 2023, and PDL meeting on March 15, 2023, were approved as written.

Department Update: The Department is reminding all providers that the Public Health Emergency (PHE) is ending on May 11, 2023. Therefore, providers are strongly encouraged to check their provider-specific webpage for more information about which flexibilities will be discontinued and their effective dates. Effective May 12, 2023, specifically for pharmacy coverage, prior authorizations will no longer be automatically renewed, refill flexibilities will be returning to pre-PHE limits, and only specified maintenance medications, listed in the Prescription Drug Program Provider Manual, will be permitted to be filled for a 90-day supply.

PREFERRED DRUG LIST MEETING

Results of the Board review of Group 3 (Red category):

CLASS	DRUG NAME	2023 RECOMMENDATIONS	Grandfathered
ANTIBIOTICS, GI	Rebyota® - ND	Must have metronidazole and vancomycin.	No
ANTIFUNGALS, ORAL	Vivjoa® - ND Brexafemme® - NI	Must have terbinafine and fluconazole. Must have 1 of clotrimazole or nystatin. Continue PA criteria on ketoconazole. <i>*The Board was notified of a request to add voriconazole as a “must have” to the Preferred Drug List. After discussion, the consensus was that it is not a “must have” agent, as non-preferred products are available to providers if there is support/evidence the preferred product options are</i>	No

CLASS	DRUG NAME	2023 RECOMMENDATIONS	Grandfathered
		<i>inappropriate for the specific case.</i>	
ANTIPSORIATICS, TOPICAL	Vtama®, Zoryve® - ND	Class effect. Must have one topical formulation and a scalp formulation. Continue PA criteria.	No
ANTIVIRALS, ORAL (HSV/INFLUENZA)	Xofluza® - NI	HSV Antivirals - Class effect. INFLUENZA Antivirals - Must have both oseltamivir and baloxavir marboxil.	No
CYTOKINES & CAM ANTAGONIST	Sotyktu® - ND Actemra®, Cibinqo®, Kevzara®, Kineret®, Olumiant®, Rinvoq®, Skyrizi®, Stelara®, adalimumab biosimilars - NI	Therapeutic alternatives. Do not add anakinra (Kineret®) due to inferior efficacy and increased toxicity. Grandfather.	Yes
IMMUNOMODULATORS, ATOPIIC DERMATITIS	Dupixent®, Opzelura® - NI	Therapeutic alternatives. Continue PA criteria.	No
IMMUNOMODULATORS, TOPICAL	Hyftor® - ND	With the addition of an agent with a different mechanism of action, the Board requested recommendation be changed from class effect to therapeutic alternatives.	No
IMMUNOSUPPRESSANTS	Cellcept® - NI	Must have an entity of azathioprine, cyclosporine, mycophenolate, sirolimus and tacrolimus. Grandfather.	Yes

The Board reviewed the blue category in advance of the meeting. Kathy from Magellan reported on new generics, updated indications, and drug availability changes in this category. This category of drugs has no new clinically significant information since last review. Board recommendations for Group 2 (Blue category) from 2022 were retained. The recommendations are as follows:

CLASS	2023 RECOMMENDATIONS	Grandfathered
ACNE AGENTS	BENZOYL PEROXIDE COMBOS - Class effect. BENZOYL PEROXIDE AGENTS - Class effect. CLINDAMYCIN AGENTS - Class effect. SODIUM SULFACETAMIDE AGENTS - Class effect. TOPICAL RETINOIDS & COMBOS - Class effect. ERYTHROMYCIN TOPICAL - Class effect.	No
ANTI-ALLERGENS, ORAL	Continue with PA criteria.	No

CLASS	2023 RECOMMENDATIONS	Grandfathered
ANTIBIOTICS, INHALED	Therapeutic alternatives.	No
ANTIBIOTICS, TOPICAL	Must have a mupirocin product.	No
ANTIBIOTICS, VAGINAL	Therapeutic alternatives.	No
ANTIFUNGALS, TOPICAL	Therapeutic alternatives for approved indications.	No
ANTI-HISTAMINES, MINIMALLY SEDATING	Class effect. Must have one single ingredient agent.	No
ANTINEOPLASTIC AGENTS, TOPICAL	Therapeutic alternatives.	No
ANTIPARASITICS, TOPICAL	Therapeutic alternatives.. Continue PA criteria.	No
ANTIVIRALS, TOPICAL	Class effect.	No
BLADDER RELAXANTS	Class effect. Must have 1 long-acting agent (either by half-life or dosage form).	No
BPH AGENTS	ALPHA BLOCKERS - Class effect. ANDROGEN HORMONE INHIBITORS/COMBOS - Class effect. PDE-5 for BPH - Tadalafil will be non-preferred. Continue with PA criteria.	No
BRONCHODILATORS, BETA AGONISTS	BETA AGONIST, LONG-ACTING - Class effect. BETA AGONIST, SHORT-ACTING - Class effect.	No
CEPHALOSPORINS & RELATED AGENTS	2 nd GENERATION - Class effect. 3 rd GENERATION - Class effect.	No
COPD AGENTS	Class effect. Must have a nebulizer product and a long-acting combination product.	No
EPINEPHRINE, SELF- INJECTED	Class effect.	No
FLUOROQUINOLONES, ORAL	2 nd GENERATION - Class effect. Must have ciprofloxacin. 3 rd GENERATION - Class effect.	No
GLUCOCORTICOIDS, INHALED	Class effect.	No
GLUCOCORTICOIDS, ORAL	SHORT ACTING - cortisone, hydrocortisone - Therapeutic alternatives. INTERMEDIATE ACTING - methylprednisolone, prednisone, and prednisolone - Therapeutic alternatives, must include a dosepak. LONG ACTING - betamethasone, dexamethasone - Therapeutic alternatives. BUDESONIDE - Must have 1 budesonide. DEFLAZACORT - Continue PA criteria.	No

CLASS	2023 RECOMMENDATIONS	Grandfathered
HEPATITIS C AGENTS	RIBAVIRINS - Class effect. PEGYLATED INTERFERONS - Do not add. ALL OTHERS - Therapeutic alternatives. Must have a pangenotypic agent. Continue with existing PA criteria. Grandfather.	Yes
INTRANASAL RHINITIS AGENTS	NASAL STEROIDS - Class effect. NASAL ANTIHISTAMINES & OTHERS - Class effect.	No
LEUKOTRIENE MODIFIERS	Must have montelukast.	No
MACROLIDES & KETOLIDES	Class effect. Must have azithromycin, clarithromycin, and erythromycin.	No
METHOTREXATE AGENTS	Must have one oral and one injectable agent.	No
ROSACEA AGENTS, TOPICAL	Must have one metronidazole product.	No
SMOKING CESSATION	Must have a nicotine patch and either nicotine gum or lozenge. Must have varenicline.	No
STERIODS, TOPICAL	LOW, MEDIUM, HIGH, and VERY HIGH POTENCY CLASSES - Class effect for each class. Must have 1 cream and 1 ointment from each category.	No
TETRACYCLINES	Must have doxycycline.	No

There were no Group 1 (green category) drugs to review.

The meeting was adjourned at 1:59 p.m.

The final PDL meeting for 2023 will be held on May 24, 2023, at 1:00 p.m., in this same format.